Aptamer-decorated nanocarriers for viral adsorption: A special look at COVID-19 DOI Creative Commons

Somayeh Handali,

Mohsen Rezaei

Molecular Therapy — Nucleic Acids, Год журнала: 2024, Номер 35(3), С. 102310 - 102310

Опубликована: Авг. 15, 2024

Viral infections are one of the leading causes death in world. One main challenge fighting against these diseases is unavailability effective eradicating drugs and specific treatments. Nanocarriers aptamer-decorated nanocarriers designed to attach many targets, including viral particles. By lowering infectivity attachment capability, they add therapeutic values even without containing antiviral drugs. Nevertheless, nanoparticles (NPs) with encapsulated can display extra effects. Furthermore, it has been shown that aptamers bind particles nanocarriers, presenting promising approaches for identification viruses treatment infections. Although there no satisfying literature revealing strong potential nanotechnology COVID-19, following information provide new perspectives upcoming investigations pertaining developing aptamer-nanocarrier agents COVID-19.

Язык: Английский

Machine learning-powered, high-affinity modification strategies for aptamers DOI Creative Commons

Amu Gubu,

Xin Yang, Hang Luo

и другие.

Acta Materia Medica, Год журнала: 2025, Номер 4(1)

Опубликована: Янв. 1, 2025

The binding affinity of aptamers to targets has a crucial role in the pharmaceutical and biosensing effects. Despite diverse post-systematic evolution ligands by exponential enrichment (post-SELEX) modifications explored aptamer optimization, accurate prediction high-affinity modification strategies remains challenging. Sclerostin, which antagonizes Wnt signaling pathway, negatively regulates bone formation. Our screened sclerostin was previously shown exert anabolic potential. In current study, an interactive methodology involving exchange mutual information between experimental endeavors machine learning initially proposed design post-SELEX strategy for aptamers. After four rounds training (a total 422 modified aptamer-target datasets with types sites), antifcial intelligence model high predictive accuracy correlation coefficient 0.82 predicted actual affinities obtained. Notably, learning-powered selected from this work exhibited 105-fold higher (picomole level K D value) 3.2-folds greater Wnt-signal re-activation effect compared naturally unmodified This approach harnessed power predict most promising

Язык: Английский

Процитировано

0

Elucidating the molecular docking and binding dynamics of aptamers with spike proteins across SARS-CoV-2 variants of concern DOI Creative Commons
Irwin A. Quintela,

Tyler Vasse,

D. Z. Jian

и другие.

Frontiers in Microbiology, Год журнала: 2025, Номер 16

Опубликована: Фев. 14, 2025

DNA aptamers with high binding affinity against SARS-CoV-2 spike proteins have been selected and analyzed. To better understand the affinities between (S-proteins) of relevant variants concerns (VOCs), in silico vitro characterization are excellent approaches to implement. Here, we identified generated aptamer sequences targeting S-protein VOCs through systematic evolution ligands by exponential enrichment (SELEX). In , prediction was conducted, followed a step-by-step workflow for secondary tertiary structures determination, modeling, molecular docking target S-protein. The strategy limited only providing predictions possible outcomes based on scores, ranking complemented analysis using direct enzyme-linked oligonucleotides assay (ELONA), which showed dissociation constants ( K d ) within 32 nM–193 nM range across three significant VOCs. These highly specific (Alpha Apt, Delta Omicron Apt) can be further studied as potential candidates both diagnostic therapeutic applications.

Язык: Английский

Процитировано

0

Replication Features of SARS-CoV-2 and Advantages of Targeting S Protein with Aptamers to Block Viral Entry DOI Creative Commons
Jun Zheng,

Qiuxia Pang,

Zhaoying Fu

и другие.

ACS Omega, Год журнала: 2025, Номер unknown

Опубликована: Апрель 21, 2025

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus of the coronaviridae family. The enters cell through binding to corresponding receptor angiotensin-converting enzyme (ACE2) on host membrane with spike protein (S protein) its envelope; thus, we can design inhibitors that bind S block entry into cells. Aptamers are single stranded DNA or RNA molecules form specific three-dimensional structures and their target high affinity specificity thus promising candidates for inhibitors. This paper reviews replication cycle mechanisms SARS-CoV-2 as well preparation principle characteristics aptamers, features discussion advantages using aptamers prevent from infecting cells, finally summarizes research progress in protein-blocking aptamers.

Язык: Английский

Процитировано

0

A patent review of anti-coronavirus agents targeting the spike-ACE2 interaction (2019–present) DOI
Xing Huang, Heng Gao, Jiwei Zhang

и другие.

Expert Opinion on Therapeutic Patents, Год журнала: 2025, Номер unknown

Опубликована: Апрель 22, 2025

The Angiotensin-converting enzyme 2 (ACE2) receptor, crucial for coronavirus recognition of host cells, is a key target therapeutic intervention against SARS-CoV-2 and related coronaviruses. Therefore, thoroughly investigating the interaction mechanism between ACE2 Spike protein (S protein), as well developing targeted inhibitors based on this mechanism, vital effectively controlling spread preventing potential future pandemics caused by other This article comprehensively reviews mechanisms underlying ACE2-S that facilitates entry into cells. It also analyzes patent landscape regarding targeting interface since 2019. In five years outbreak SARS-CoV-2, numerous methods design strategies have been employed to develop innovative therapeutics Among these approaches, both receptor S gained significant interest due their in blocking various Despite facing challenges similar protein-protein inhibitors, progress has made through virtual screening, covalent binding, peptide modification strategies. However, obstacles persist clinical translation, necessitating multidisciplinary strategy integrates state-of-the-art methodologies optimize S-ACE2 interface-targeted drug discovery.

Язык: Английский

Процитировано

0

Aptamer-engaged nanotherapeutics against SARS-CoV-2 DOI Creative Commons
Jing Zhang, Dan Wang, Chun Kit Kwok

и другие.

Discover Nano, Год журнала: 2025, Номер 20(1)

Опубликована: Апрель 27, 2025

The COVID-19 pandemic, caused by the virus SARS-CoV-2 infection, has underscored critical importance of rapid and accurate therapeutics. neutralization is paramount in controlling spread impact COVID-19. In this context, integration aptamers aptamer-related nanotherapeutics presents a valuable scientifically significant approach. Despite potential, current reviews area are often not comprehensive specific enough to encapsulate full scope therapeutic principles, strategies, advancements, challenges. This review aims fill that gap providing an in-depth examination role their related molecular medicine We first introduce unique properties, selection, recognition mechanism bind with high affinity various targets. Next, we delve into potential aptamers, focusing on ability inhibit viral entry replication, as well modulate host immune response. nucleic acid nanomedicine explored. Finally, address challenges future perspectives aptamer therapeutics, including issues stability, delivery, manufacturing scalability. conclude underscoring continued research development field meet ongoing posed pandemics. Our will be resource for researchers clinicians interested latest developments at intersection biology, nanotechnology, infectious disease management.

Язык: Английский

Процитировано

0

Analyzing aptamer structure and interactions: in silico modelling and instrumental methods DOI
Daria O. Malysheva, М. А. Дымова, Vladimir A. Richter

и другие.

Biophysical Reviews, Год журнала: 2024, Номер 16(6), С. 685 - 700

Опубликована: Ноя. 20, 2024

Язык: Английский

Процитировано

2

Aptamer-decorated nanocarriers for viral adsorption: A special look at COVID-19 DOI Creative Commons

Somayeh Handali,

Mohsen Rezaei

Molecular Therapy — Nucleic Acids, Год журнала: 2024, Номер 35(3), С. 102310 - 102310

Опубликована: Авг. 15, 2024

Viral infections are one of the leading causes death in world. One main challenge fighting against these diseases is unavailability effective eradicating drugs and specific treatments. Nanocarriers aptamer-decorated nanocarriers designed to attach many targets, including viral particles. By lowering infectivity attachment capability, they add therapeutic values even without containing antiviral drugs. Nevertheless, nanoparticles (NPs) with encapsulated can display extra effects. Furthermore, it has been shown that aptamers bind particles nanocarriers, presenting promising approaches for identification viruses treatment infections. Although there no satisfying literature revealing strong potential nanotechnology COVID-19, following information provide new perspectives upcoming investigations pertaining developing aptamer-nanocarrier agents COVID-19.

Язык: Английский

Процитировано

0